George Farmer
Stock Analyst at Scotiabank
(2.51)
# 2,311
Out of 5,147 analysts
70
Total ratings
47.37%
Success rate
3.06%
Average return
Main Sectors:
Top Industries:
Stocks Rated by George Farmer
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| BMEA Biomea Fusion | Maintains: Sector Outperform | $30 → $10 | $1.37 | +629.93% | 4 | Aug 6, 2025 | |
| ACLX Arcellx | Maintains: Sector Outperform | $93 → $133 | $113.79 | +16.88% | 4 | Jul 31, 2025 | |
| INMB INmune Bio | Downgrades: Sector Underperform | $23 → $0.6 | $1.29 | -53.49% | 3 | Jul 1, 2025 | |
| URGN UroGen Pharma | Maintains: Sector Outperform | $23 → $47 | $21.70 | +116.59% | 1 | Jun 13, 2025 | |
| SNDX Syndax Pharmaceuticals | Maintains: Sector Perform | $16 → $17 | $21.71 | -21.70% | 4 | May 6, 2025 | |
| TARA Protara Therapeutics | Initiates: Sector Outperform | $12 | $6.36 | +88.68% | 1 | Apr 16, 2025 | |
| TPST Tempest Therapeutics | Downgrades: Sector Perform | $91 → $9 | $2.28 | +294.74% | 4 | Apr 10, 2025 | |
| JANX Janux Therapeutics | Maintains: Sector Perform | $62 → $41 | $13.61 | +201.25% | 4 | Feb 28, 2025 | |
| NAMS NewAmsterdam Pharma Company | Maintains: Sector Outperform | $47 → $52 | $35.46 | +46.64% | 4 | Feb 27, 2025 | |
| BMRN BioMarin Pharmaceutical | Maintains: Sector Perform | $78 → $80 | $61.73 | +29.60% | 8 | Feb 20, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sector Outperform | $244 → $224 | $191.82 | +16.78% | 4 | Feb 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Sector Outperform | $102 | $33.84 | +201.42% | 1 | Feb 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sector Perform | $18 → $10 | $8.73 | +14.55% | 2 | Jan 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Sector Outperform | $439 → $715 | $766.92 | -6.77% | 5 | Nov 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sector Outperform | $20 → $23 | $5.89 | +290.49% | 2 | Oct 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Sector Outperform | $20 | $0.74 | +2,584.92% | 1 | Sep 30, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sector Outperform | $70 → $76 | $19.00 | +300.00% | 4 | Aug 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Sector Outperform | $13 | $2.74 | +374.45% | 1 | Mar 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | $109 | $53.57 | +103.47% | 3 | Nov 17, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $94 → $87 | $101.27 | -14.09% | 5 | Nov 6, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $33 | $2.70 | +1,122.22% | 1 | Oct 27, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $40 | $1.02 | +3,821.57% | 1 | Jul 20, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $20 → $27 | $44.06 | -38.72% | 3 | May 6, 2020 |
Biomea Fusion
Aug 6, 2025
Maintains: Sector Outperform
Price Target: $30 → $10
Current: $1.37
Upside: +629.93%
Arcellx
Jul 31, 2025
Maintains: Sector Outperform
Price Target: $93 → $133
Current: $113.79
Upside: +16.88%
INmune Bio
Jul 1, 2025
Downgrades: Sector Underperform
Price Target: $23 → $0.6
Current: $1.29
Upside: -53.49%
UroGen Pharma
Jun 13, 2025
Maintains: Sector Outperform
Price Target: $23 → $47
Current: $21.70
Upside: +116.59%
Syndax Pharmaceuticals
May 6, 2025
Maintains: Sector Perform
Price Target: $16 → $17
Current: $21.71
Upside: -21.70%
Protara Therapeutics
Apr 16, 2025
Initiates: Sector Outperform
Price Target: $12
Current: $6.36
Upside: +88.68%
Tempest Therapeutics
Apr 10, 2025
Downgrades: Sector Perform
Price Target: $91 → $9
Current: $2.28
Upside: +294.74%
Janux Therapeutics
Feb 28, 2025
Maintains: Sector Perform
Price Target: $62 → $41
Current: $13.61
Upside: +201.25%
NewAmsterdam Pharma Company
Feb 27, 2025
Maintains: Sector Outperform
Price Target: $47 → $52
Current: $35.46
Upside: +46.64%
BioMarin Pharmaceutical
Feb 20, 2025
Maintains: Sector Perform
Price Target: $78 → $80
Current: $61.73
Upside: +29.60%
Feb 13, 2025
Maintains: Sector Outperform
Price Target: $244 → $224
Current: $191.82
Upside: +16.78%
Feb 13, 2025
Initiates: Sector Outperform
Price Target: $102
Current: $33.84
Upside: +201.42%
Jan 8, 2025
Maintains: Sector Perform
Price Target: $18 → $10
Current: $8.73
Upside: +14.55%
Nov 5, 2024
Upgrades: Sector Outperform
Price Target: $439 → $715
Current: $766.92
Upside: -6.77%
Oct 18, 2024
Maintains: Sector Outperform
Price Target: $20 → $23
Current: $5.89
Upside: +290.49%
Sep 30, 2024
Initiates: Sector Outperform
Price Target: $20
Current: $0.74
Upside: +2,584.92%
Aug 12, 2024
Maintains: Sector Outperform
Price Target: $70 → $76
Current: $19.00
Upside: +300.00%
Mar 14, 2024
Initiates: Sector Outperform
Price Target: $13
Current: $2.74
Upside: +374.45%
Nov 17, 2020
Downgrades: Market Perform
Price Target: $109
Current: $53.57
Upside: +103.47%
Nov 6, 2020
Maintains: Market Perform
Price Target: $94 → $87
Current: $101.27
Upside: -14.09%
Oct 27, 2020
Initiates: Outperform
Price Target: $33
Current: $2.70
Upside: +1,122.22%
Jul 20, 2020
Initiates: Outperform
Price Target: $40
Current: $1.02
Upside: +3,821.57%
May 6, 2020
Maintains: Market Perform
Price Target: $20 → $27
Current: $44.06
Upside: -38.72%